Anika Therapeutics (ANIK) Accumulated Expenses (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Accumulated Expenses data on file, last reported at $14.6 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $14.6 million, up 146.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.6 million (up 146.0% YoY), and the FY2025 annual result was $15.9 million, up 16.95% from the prior year.
• Accumulated Expenses fell to $14.6 million in Q1 2026 per ANIK's latest filing, from $15.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $19.7 million in Q1 2023 and troughed at $5.9 million in Q1 2025.
• A 5-year average of $11.7 million and a median of $11.2 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses surged 164.78% in 2023, then slumped 56.47% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $11.3 million in 2022, then climbed by 24.44% to $14.1 million in 2023, then declined by 3.55% to $13.6 million in 2024, then advanced by 16.95% to $15.9 million in 2025, then declined by 7.81% to $14.6 million in 2026.
• Business Quant data shows ANIK's Accumulated Expenses at $14.6 million in Q1 2026, $15.9 million in Q4 2025, and $14.4 million in Q3 2025.